Initial results of a clinical trial with 146 patients in 18 hospitals show a promising success rate of up to 99 percent, the biomedical company says.

Minimally invasive device IceSense3 uses extremely cold temperatures to destroy fibroadenomas, common benign breast tumors. The Israeli invention now holds promise as a potential treatment for malignant breast tumors, after a successful clinical trial in Japan.